Viatris (VTRS) Capital Expenditures (QoQ) (2021 - 2026)
Powered by 
Analysis
Viatris (VTRS) Capital Expenditures (QoQ) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.33% |
| Mar 31, 2026 | -79.69% |
| Dec 31, 2025 | 126.38% |
| Sep 30, 2025 | 64.08% |
| Jun 30, 2025 | 24.18% |
| Mar 31, 2025 | -69.66% |
| Dec 31, 2024 | 82.34% |
| Sep 30, 2024 | 30.95% |
| Jun 30, 2024 | 18.07% |
| Mar 31, 2024 | -69.91% |
| Dec 31, 2023 | 72.58% |
| Sep 30, 2023 | 41.45% |
| Jun 30, 2023 | 41.84% |
| Mar 31, 2023 | -68.90% |
| Dec 31, 2022 | 47.93% |
| Sep 30, 2022 | 23.84% |
| Jun 30, 2022 | 30.08% |
| Mar 31, 2022 | -67.33% |
| Dec 31, 2021 | 63.14% |
| Sep 30, 2021 | 35.50% |